Jul 15
LIPO · Lipella Pharmaceuticals Inc.
$0.00
At close · Nov 11
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 14, 2025
Substantial doubt about the company's ability to continue as a going concern.
“These factors individually and collectively raise substantial doubt about the Company's ability to continue as a going concern. The accompanying unaudited condensed financial statements do not include any adjustments that may result from this uncertainty.”View the 10-Q filed Nov 14, 2025
Market Cap
$2,773
Shares
4.62M
Volume · Nov 11
43.34K
Avg daily vol (3M)
3997
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.00
Open$0.00
Day$0.00–0.00
52W close$0.00–0.54
Avg vol 30d12K
Short int1K · 0.0% of shares · 1.9d
Short vol99%
DataDec 2022–Nov 2026
Filing10-Q · Nov 14
Latest documents
2026
Mar 31
Feb 4
Current report
8-K
Events of Feb 3
Director or officer change, or executive pay
AI summary on its way
2025
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $1.25M
Diluted EPS -$0.28
Oct 21
Current report
8-K
Events of Oct 20
Director or officer change, or executive pay
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$389,783
Trailing 12 months
Net income (TTM)
−$5.33M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
-1,387.9%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.86M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+306.5%
Year over year · more shares
Price change (1Y)
-99.9%
Trailing year
Short interest
0.0%
Latest settlement · 1.9 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.72
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−100%
below
Price vs 50-day avg
−98%
below
RSI (14)
36
neutral
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+50%
trailing
6-month return
−100%
trailing
YTD return
−100%
this year
Relative strength
−102%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.03% of shares out · ▼ -0.1% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 2-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
Revenue growth
+19%
Y/Y
EPS growth
+22%
Y/Y
Free cash flow
$-4.0M
Quant / Vol
risk profile
Volatility
427%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
533.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−100%
Bearish
Price vs 50-day avg
−98%
Bearish
RSI (14)
36
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.03% of shares out · ▼ -0.1% MoM · 1.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
4 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $1
vs 200-day avg -100%
vs 50-day avg -98%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIPO
this stock
Lipella Pharmaceuticals Inc.
|
$2,773 | -99.7% | +19.3% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$137.57B | +19.7% | +46.2% | 34.9 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.40B | +23.2% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$93.61B | +684.5% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.55B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
4
- % held
- 0.1%
- Net QoQ
- -10.6K sh
- Top holder
- Tower Research Capital LL…
Held
Float
Short & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIPO | +20.0% | +50.0% | -99.7% | +0.0% | -99.7% |
| SPY | -0.9% | -1.3% | +2.3% | +0.5% | +11.4% |
| vs SPY | +20.9% | +51.3% | -102.0% | -0.5% | -111.1% |